Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Pre-clinical characterization and process development of a BCMA-directed CAR NK-cell therapy product for relapsed/refractory multiple myeloma

Charles Yin, Angela Hamie, Janna Kozuska et al. Nov 03, 2025 pp. 7650-7650 10.1182/blood-2025-7650

Abstract The burgeoning field of cellular therapy, in particular chimeric antigen receptor (CAR) T-cell therapy, has revolutionized the trea...

Cost and quality of life analysis associated with allogeneic hematopoietic progenitor transplantation

Sara Fernandez-Luis, Paloma Lanza, Marina Barreda et al. Nov 03, 2025 pp. 2480-2480 10.1182/blood-2025-2480

Abstract Introduction Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a complex procedure that involves significant clinica...

Platelet decrease and efficacy of platelet-rich plasma return for CAR-T lymphocyte apheresis in low-weight patients

Takahiro Shima, Tomoko Henzan, Ikumi Yamanaka et al. Nov 03, 2025 pp. 7702-7702 10.1182/blood-2025-7702

Abstract Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a transformative treatment for relapsed or refractory acute lymphobla...

Implicating a functional domain (SPOC) of RBM15 in the pathogenesis of RBM15::MKL1 fusion protein-induced acute megakaryoblastic leukemia

Amos Espinosa, Madeline Mayday, Mi Chen et al. Nov 03, 2025 pp. 6755-6755 10.1182/blood-2025-6755

Abstract In acute megakaryoblastic leukemia (AMKL), immature megakaryoblasts accumulate due to excessive proliferation and failure to termin...

Role of DNA damage sensing and TP53 function as modulators of sensitivity to calicheamicin-based antibody-drug conjugates (ADCs) for acute leukemia

Camryn Pettenger-Willey, George Laszlo, Frances Cole et al. Nov 03, 2025 pp. 6811-6811 10.1182/blood-2025-6811

Abstract Background: ADCs have long been pursued to improve outcomes in acute leukemia, with focus on CD33 (for acute myeloid leukemia [AML]...

Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data

Piyanuch Kongtim, Andrew Portuguese, Soyoung Kim et al. Nov 03, 2025 pp. 109-109 10.1182/blood-2025-109

Abstract Introduction: Reduced intensity and non-myeloablative (RIC/NMA) conditioning regimens are routinely utilized in allogeneic hematopo...

Myeloproliferative neoplasms in Mexico: An analysis of clinical features, driver mutations, and disease progression patterns in a case series.

Carlos Chavez-Trillo, Katya Unzueta-Villalobos, Sofia Bandera-Lopez et al. Nov 03, 2025 pp. 7328-7328 10.1182/blood-2025-7328

Abstract Myeloproliferative neoplasms (MPNs) are chronic hematologic malignancies characterized by clonal myeloid proliferation, risking pro...

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Karan Chohan, Lei Feng, Hunter Cochran et al. Nov 03, 2025 pp. 1852-1852 10.1182/blood-2025-1852

Abstract Introduction: Brentuximab vedotin (BV) and nivolumab (N) have resulted in significant progress in the treatment of advanced-stage H...

HEM-ismart: An international proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children

Andrej Lissat, Francisco Bautista, Olli Lohi et al. Nov 03, 2025 pp. 1582-1582 10.1182/blood-2025-1582

Abstract Background and Significance The prognosis of pediatric patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) o...

Elevation of liver health biomarkers before and after etranacogene dezaparvovec gene therapy in hemophilia B: Associations with long-term clinical outcomes

Wolfgang Miesbach, Steven Pipe, Cedric Hermans et al. Nov 03, 2025 pp. 6093-6093 10.1182/blood-2025-6093

Abstract Introduction Gene therapy with etranacogene dezaparvovec has emerged as a transformative treatment for individuals with hemophilia...

Acquired regions of homozygosity in adult B-cell acute lymphoblastic leukemia: Insights from a machine learning–powered analysis of genomic data from a multicenter cohort

Gianfranco Lapietra, Juan Manuel Rosa-Rosa, Mireia Morgades et al. Nov 03, 2025 pp. 6879-6879 10.1182/blood-2025-6879

Abstract INTRODUCTION Acquired regions of homozygosity (aROHs), due to mitotic recombination between homologous chromoso...

In multiple myeloma patients, autologous stem cell transplants abrogate the difference of treating them with two or three drug combinations: Real world data from a single institution in a middle-income country.

Sofía Chávez Martínez, Lidia Alberto López, Olivia Lira Lara et al. Nov 03, 2025 pp. 7604-7604 10.1182/blood-2025-7604

Abstract Background: Currently, the standard treatment of MM is a three-drug regimen that includes immunomodulators, corticosteroids, and pr...

Orelabrutinib combined with R-CDOP regimen for first-line treatment of diffuse large B-cell lymphoma with high-risk CNS-IPI

Xibin Xiao, Wenbin Qian, Lixia Sheng et al. Nov 03, 2025 pp. 5460-5460 10.1182/blood-2025-5460

Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) relapse in the central nervous system (CNS) is a highly destructive complication...

Targeting β-catenin nuclear export and protein degradation in high-risk acute lymphoblastic leukemia

Jodi Forward, Kadriye Nehir Cosgun, Esma Fera et al. Nov 03, 2025 pp. 3371-3371 10.1182/blood-2025-3371

Abstract Background and Significance: A recurrent, gain-of-function mutation in the nuclear export molecule XPO1 (E571K) has been identified...

Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study

Huang He, Qingqing Cai, Yi Xia et al. Nov 03, 2025 pp. 5363-5363 10.1182/blood-2025-5363

Abstract Background Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL), accounting for approximately 20-30% of...

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

Heather Landau, Shahzad Raza, Aaron Rosenberg et al. Nov 03, 2025 pp. 696-696 10.1182/blood-2025-696

Abstract Background: No FDA approved treatments exist for relapsed/refractory (RR) AL Amyloidosis. Chimeric antigen receptor T-cell (CAR-T)...

Clone-specific epigenetic regulatory mechanisms in ASXL1-mutant chronic myelomonocytic leukemia

Moritz Binder, Terra Lasho, Jenna Fernandez et al. Nov 03, 2025 pp. 234-234 10.1182/blood-2025-234

Abstract Introduction: ASXL1-mutant (mt) Chronic Myelomonocytic Leukemia (CMML) is an aggressive myeloid neoplasm characterized by increased...

Black lives advocating for clot knowledge (B.L.A.C.K) national blood clot alliance church bus tour: A community-based blood clot education and awareness campaign

Dana Angelini, Rushad Patell, Wei Wei et al. Nov 03, 2025 pp. 829-829 10.1182/blood-2025-829

Abstract Background: Black Americans are disproportionally affected by venous thromboembolism (VTE) and experience higher incidence, greater...

Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients.

Sushmita Khadka, Anushi Patel, Jonathan Zhao et al. Nov 03, 2025 pp. 1882-1882 10.1182/blood-2025-1882

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, with a significant proportion...

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Ruike Yan, Chun Gan, Ning Dai et al. Nov 03, 2025 pp. 2299-2299 10.1182/blood-2025-2299

Abstract Background:Although the overall survival of multiple myeloma (MM) has improved significantly, patients with ultra-high-risk feature...

Real world outcomes comparing the use of GLP-1 receptor agonists in patients with CML and comorbid obesity: A propensity score matched analysis from global federated health research network

Arshi Syal, Yajur Arya, Angimar Uriepero et al. Nov 03, 2025 pp. 4635-4635 10.1182/blood-2025-4635

Abstract Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the treatment of type 2 diabetes and obesity. Em...

NLRP6 regulates ZAP-70-erk signaling in both murine and human T cells and influences acute graft-versus-host disease(GVHD)

Eri Matsuki, Masahiro Miyata, Jana Gawron et al. Nov 03, 2025 pp. 4090-4090 10.1182/blood-2025-4090

Abstract The Nlrp6 (NOD-like receptor family pyrin domain-containing 6) inflammasome is essential for innate immune responses and maintainin...

A fellow-led communication skills training (CST) curriculum for hematology/oncology (HO) trainees

Ahmad Nassar, Puneet Raman, Ajit Venkatakrishnan et al. Nov 03, 2025 pp. 2870-2870 10.1182/blood-2025-2870

Abstract Background: High-quality, equitable HO care depends on clinicians' ability to effectively communicate complex,...

An orally bioavailable and dual-targeting GSPT1 and CK1α molecular glue degrader targets double-hit lymphoma cells

Shi Feng, Minghao Sun, Qingbo Hao et al. Nov 03, 2025 pp. 3308-3308 10.1182/blood-2025-3308

Abstract Therapeutic options for aggressive and high-risk lymphomas, such as double-hit lymphoma (DHL), remain limited. As a novel therapeut...

Double-blind randomized study to evaluate the effect of hydroxycarbamide on albuminuria in adults with sickle cell disease: Sikamic (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

Pablo Bartolucci, Saliou Diop, Giovanna Cannas et al. Nov 03, 2025 pp. 2938-2938 10.1182/blood-2025-2938

Abstract Background The optimal therapeutic strategies for adult sickle cell disease (SCD) patients with nephropathy remains to be determine...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page